Search results for " KIDNEY"

showing 10 items of 404 documents

NephroCheck: should we consider urine osmolality?

2019

medicine.medical_specialtyLetterCritical Care030232 urology & nephrologyMEDLINEUrine030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineAcute Kidney Injury; Biomarkers Humans Insulin-Like Growth Factor Binding Proteins Research Design Tissue Inhibitor of Metalloproteinase-2 Urine Osmolar ConcentrationOsmolar Concentration03 medical and health sciences0302 clinical medicinemedicineHumansTissue Inhibitor of Metalloproteinase-2Intensive Care Medicinebusiness.industryOsmolar Concentrationlcsh:Medical emergencies. Critical care. Intensive care. First aidlcsh:RC86-88.9Acute Kidney InjuryInsulin-Like Growth Factor Binding ProteinsResearch DesignEmergency medicineUrine osmolalitybusinessBiomarkersCritical Care
researchProduct

Lipoprotein abnormalities in chronic kidney disease and renal transplantation

2021

Chronic kidney disease (CKD) is one of the most important risk factors for cardiovascular disease (CVD). Despite the kidney having no direct implications for lipoproteins metabolism, advanced CKD dyslipidemia is usually present in patients with CKD, and the frequent lipid and lipoprotein alterations occurring in these patients play a role of primary importance in the development of CVD. Although hypertriglyceridemia is the main disorder, a number of lipoprotein abnormalities occur in these patients. Different enzymes pathways and proteins involved in lipoprotein metabolism are impaired in CKD. In addition, treatment of uremia may modify the expression of lipoprotein pattern as well as deter…

medicine.medical_specialtyLipoproteins030232 urology & nephrologyDiseaseReview030204 cardiovascular system & hematologyurologic and male genital diseasesGastroenterologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineInternal medicineChronic kidney diseasemedicinelcsh:ScienceEcology Evolution Behavior and SystematicsKidneybusiness.industryHypertriglyceridemiaPaleontologymedicine.diseaseCardiovascular diseaseLipidsUremiafemale genital diseases and pregnancy complicationsTransplantationmedicine.anatomical_structureSpace and Planetary Sciencelipids (amino acids peptides and proteins)lcsh:QbusinessDyslipidemiaKidney diseaseLipoprotein
researchProduct

Comparison of two delayed strategies for renal replacement therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, open-label, ra…

2021

International audience; BACKGROUND: Delaying renal replacement therapy (RRT) for some time in critically ill patients with severe acute kidney injury and no severe complication is safe and allows optimisation of the use of medical devices. Major uncertainty remains concerning the duration for which RRT can be postponed without risk. Our aim was to test the hypothesis that a more-delayed initiation strategy would result in more RRT-free days, compared with a delayed strategy. METHODS: This was an unmasked, multicentre, prospective, open-label, randomised, controlled trial done in 39 intensive care units in France. We monitored critically ill patients with severe acute kidney injury (defined …

medicine.medical_specialtyMESH: Acute Kidney Injury[SDV]Life Sciences [q-bio]medicine.medical_treatmentPopulation030204 cardiovascular system & hematologyurologic and male genital diseasesMESH: Severity of Illnes Index03 medical and health sciencesMESH: Aged 80 and over0302 clinical medicineOliguriaIntensive careInternal medicineMedicineMESH: Time-to-Treatment030212 general & internal medicineRenal replacement therapyeducationBlood urea nitrogenMESH: Agededucation.field_of_studyMESH: HumansMESH: Middle Agedbusiness.industryHazard ratioAcute kidney injuryGeneral Medicinemedicine.diseaseMESH: MaleMESH: Prospective Studies3. Good health[SDV] Life Sciences [q-bio]MESH: FranceMESH: Intensive Care Unitsmedicine.symptomMESH: Renal Remplacement TherapybusinessMESH: FemaleKidney diseaseThe Lancet
researchProduct

Sodium-glucose cotransporter 2 inhibition : towards an indication to treat diabetic kidney disease

2020

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have clearly demonstrated their beneficial effect in diabetic kidney disease (DKD) on top of the standard of care [blood glucose control, renin–angiotensin system blockade, smoking cessation and blood pressure (BP) control], even in patients with overt DKD. However, the indication of this drug class is still blood glucose lowering in type 2 diabetic patients with estimated glomerular filtration rate >45mL/min/1.73m2. Based on the new evidence, several scientific societies have emphasized the preferential prescription of SGLT2i for patients at risk of heart failure or kidney disease, but still within the limits set by health authorities. A r…

medicine.medical_specialtyMedicina030232 urology & nephrologyRenal functionReviewsType 2 diabetes030204 cardiovascular system & hematologyDiabetic nephropathy03 medical and health sciences0302 clinical medicineSodium-Glucose Transporter 2Internal medicineDiabetes mellitusDiabetic nephropathiesmedicineChronic renal failureHumansDiabetic NephropathiesDiabetic kidney diseaseESRDSodium-Glucose Transporter 2 InhibitorsTransplantationbusiness.industryType 2 diabetesNefropaties diabètiquesmedicine.diseasePrognosisBlood pressureDiabetes Mellitus Type 2NephrologyHeart failureSodium/Glucose Cotransporter 2Insuficiència renal crònicabusinessSGLT2 inhibitorsKidney disease
researchProduct

GLP-1 Receptor agonists and diabetic kidney disease: A call of attention to nephrologists

2020

Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease (CKD) and end-stage renal disease (ESKD), and diabetic kidney disease (DKD) is a major cause of morbidity and mortality in diabetes. Despite advances in the nephroprotective treatment of T2DM, DKD remains the most common complication, driving the need for renal replacement therapies (RRT) worldwide, and its incidence is increasing. Until recently, prevention of DKD progression was based around strict blood pressure (BP) control, using renin–angiotensin system blockers that simultaneously reduce BP and proteinuria, adequate glycemic control and control of cardiovascular risk factors. Glucagon-like peptide-1 r…

medicine.medical_specialtyMedicinaRenal functionlcsh:Medicine030209 endocrinology & metabolismReview030204 cardiovascular system & hematologyHypoglycemiaurologic and male genital diseases03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineChronic kidney diseaseMedicineMalalties cròniquesDiabetic kidney diseaseGlycemicKidneyProteinuriaKidney diseasesbusiness.industrylcsh:RType 2 Diabetes MellitusGeneral Medicinemedicine.diseasediabetic kidney diseasemedicine.anatomical_structureChronic diseasesMalalties del ronyómedicine.symptombusinessGLP-1chronic kidney diseaseKidney disease
researchProduct

Cardiorenal Fat: A Cardiovascular Risk Factor With Implications in Chronic Kidney Disease.

2021

There is a growing interest in the potential role of adipose tissues in cardiac and renal pathophysiology, and determining the mechanisms by which fat compartments around the heart and kidneys influence cardiovascular disease is of clinical importance in both general and high-risk populations. Epicardial fat and perirenal fat have been associated with adverse outcomes in chronic kidney disease (CKD) patients. Epicardial fat is a rich source of free fatty acids and is capable of secreting inflammatory and pro-atherogenic cytokines that promote atherosclerosis through a local paracrine effect. Recent evidence has demonstrated that perirenal fat has a closer correlation with kidney diseases th…

medicine.medical_specialtyMedicine (General)renal failureAdipose tissueDiseaseReviewAdipose capsule of kidneyR5-920cardiovascular diseaseInternal medicinemedicineRisk factorKidneybusiness.industryGeneral Medicinemedicine.diseaseObesityPathophysiologyadipose tissuemedicine.anatomical_structureCardiologyMedicinebusinesscardiorenal diseasechronic kidney diseaseKidney diseaseFrontiers in medicine
researchProduct

Syndrome of autosomal recessive polycystic kidneys with skeletal and facial anomalies is not linked to the ARPKD gene locus on chromosome 6p

2000

We report on two sibs, both males, one born at 37 the other at 24 weeks of gestation, both with a syndrome similar to that seen in three sets of sibs by Gillessen-Kaesbach et al. [1993: Am J Med Genet 45:511–518]. Both propositi had polycystic kidneys and hepatic fibrosis indistinguishable from that seen in autosomal recessive polycystic kidney disease (ARPKD), and skeletal and facial anomalies. Skeletal abnormalities included “butterfly” vertebrae, square shape of pelvis, and brachymelia. The facial anomalies included hypertelorism, epicanthic folds, and anteverted nares. Additional external findings were apparently low-set ears and a short neck. Histopathological examination of the kidney…

medicine.medical_specialtyPathologyGenetic heterogeneityBiologyCystic Changemedicine.diseaseAutosomal Recessive Polycystic Kidney DiseaseEndocrinologyGenetic linkageInternal medicinemedicineCystHypertelorismmedicine.symptomGenetics (clinical)Potter SyndromeKidney diseaseAmerican Journal of Medical Genetics
researchProduct

The “bouquet of flowers” appearance in medullary sponge kidney

2018

The “bouquet of flowers” appearance is a radiological finding described for the intravenous pyelography (IVP) diagnosis of medullary sponge kidney (MSK). It refers to contrast pooling in dilated tubular structures in renal papillae, giving a striated pattern to the renal medulla, which resembles a “bouquet of flowers”

medicine.medical_specialtyPathologyMedullary Sponge KidneyRadiological and Ultrasound Technologybusiness.industryUrology030232 urology & nephrologyGastroenterologyUrography030204 cardiovascular system & hematologyHepatologyKidneyMedullary sponge kidneymedicine.diseaseDiagnosis Differential03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingTomography X-Ray ComputedbusinessAbdominal Radiology
researchProduct

Prenatal diagnosis and epidemiology of multicystic kidney dysplasia in Europe

2014

ObjectivesThe aim of this study is to describe the prenatal diagnosis and epidemiology of multicystic kidney dysplasia (MCKD). MethodsThe study is based on routinely collected data from a European database of major congenital anomalies including 13 registries with cases born in 1997-2006 and covering 1458552 births. ResultsThere were 601 MCKD cases giving an overall prevalence of 4.12 per 10000 births with regional variation. In live births, 87% of cases had an isolated renal anomaly and 13% had associated major nonrenal anomalies (chromosomal, syndrome or other major anomalies). For the cases with isolated renal anomalies, 51/386 (11%) and 7/386 (2%) choose to terminate the pregnancy or re…

medicine.medical_specialtyPediatricsPregnancyMulticystic Kidney DysplasiaFetal deathbusiness.industryObstetrics and GynecologyPrenatal diagnosismedicine.diseaseRenal anomalyEpidemiologyMedicineDetection ratebusinessGenetics (clinical)Prenatal Diagnosis
researchProduct

Left ventricular hypertrophy: not so much determinant of renal outcome?

2011

medicine.medical_specialtyPhysiologyProportional hazards modelbusiness.industryChronic kidney diseases.Renal functionLeft ventricular hypertrophyLeft ventricular hypertrophymedicine.diseaseOutcome (game theory)Chronic diseaseInternal medicineInternal MedicinemedicineCardiologyCardiology and Cardiovascular Medicinebusiness
researchProduct